Literature DB >> 16796622

Quinine sulfate inhibits invasion of some bacterial skin pathogens.

Ronni Wolf1, Maria Antonietta Tufano, Vincenzo Ruocco, Elena Grimaldi, Eleonora Ruocco, Giovanna Donnarumma, Adone Baroni.   

Abstract

BACKGROUND: As some of the many patients who receive antimalarials for the treatment of noninfective inflammatory diseases (lupus erythematosus, collagen vascular diseases, rheumatoid arthritis, and others) are also immunosuppressed because of their disease and/or treatments, and may have concomitant bacterial infections, we investigated the effect of these drugs on the growth and invasion of several bacteria that are commonly associated with skin and soft tissue infections to determine whether they could protect against such conditions and obviate the need for an additional antibiotic drug.
METHODS: The effect of quinine sulfate (QS) at concentrations of 50 and 100 microm on the entry process of Enterobacter agglomerans, Staphylococcus aureus, Pseudomonas aeruginosa, and Klebsiella pneumoniae into Caco-2 cells was studied during the infection period. The invasive efficiency was expressed as the number of viable internalized bacteria obtained by counting the colony-forming units (CFUs).
RESULTS: The invasive ability of E. agglomerans and S. aureus was significantly inhibited by 50 and 100 microm QS in a dose-dependent manner when the drug was added to Caco-2 cell monolayers during the infection period; however, QS had no significant effect on the internalization of P. aeruginosa or K. pneumoniae. DISCUSSION AND
CONCLUSIONS: Antimalarial drugs are currently widely used to treat patients with autoimmune dermatologic and rheumatologic diseases, and have also been recently proposed as additional therapy for patients with human immunodeficiency virus (HIV) infection. These patients, who are often immunocompromised, may receive a secondary advantage from these antimalarials, which may provide some protection against staphylococci (amongst the most important human pathogens causing many superficial and systemic infections) and E. agglomerans.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16796622     DOI: 10.1111/j.1365-4632.2006.02696.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  5 in total

1.  Hydroquinine Possesses Antibacterial Activity, and at Half the MIC, Induces the Overexpression of RND-Type Efflux Pumps Using Multiplex Digital PCR in Pseudomonas aeruginosa.

Authors:  Nontaporn Rattanachak; Sattaporn Weawsiangsang; Touchkanin Jongjitvimol; Robert A Baldock; Jirapas Jongjitwimol
Journal:  Trop Med Infect Dis       Date:  2022-07-30

2.  Inhibition of Toxoplasma gondii Growth by Dihydroquinine and Its Mechanisms of Action.

Authors:  Aarin M Huffman; Joseph A Ayariga; Audrey Napier; Boakai K Robertson; Daniel A Abugri
Journal:  Front Cell Infect Microbiol       Date:  2022-05-11       Impact factor: 6.073

Review 3.  Therapeutic Potentials of Antiviral Plants Used in Traditional African Medicine With COVID-19 in Focus: A Nigerian Perspective.

Authors:  Alfred Francis Attah; Adeshola Adebayo Fagbemi; Olujide Olubiyi; Hannah Dada-Adegbola; Akinseinde Oluwadotun; Anthony Elujoba; Chinedum Peace Babalola
Journal:  Front Pharmacol       Date:  2021-04-26       Impact factor: 5.810

Review 4.  Kaposi's sarcoma: etiology and pathogenesis, inducing factors, causal associations, and treatments: facts and controversies.

Authors:  Eleonora Ruocco; Vincenzo Ruocco; Maria Lina Tornesello; Alessio Gambardella; Ronni Wolf; Franco M Buonaguro
Journal:  Clin Dermatol       Date:  2013 Jul-Aug       Impact factor: 3.541

Review 5.  The Use of Antimalarial Drugs against Viral Infection.

Authors:  Sarah D'Alessandro; Diletta Scaccabarozzi; Lucia Signorini; Federica Perego; Denise P Ilboudo; Pasquale Ferrante; Serena Delbue
Journal:  Microorganisms       Date:  2020-01-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.